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Abstract Viozan TM, (Sibenadet HCI, AR-C68397AA) is a dual D 2 dopamine receptor, ~2-adrenoceptor agonist that 
combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. 
Investigation in animal models of key chronic obstructive pulmonary disease (COPD) symptoms has demonstrated that 
sibenadet effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea. The 
results of the early clinical evaluation of this novel agent are reported. 
An initial proof of concept study (Study I) aimed to determine the clinical potential of this novel agent by assessing the 
effects of three doses of sibenadet therapy relative to placebo, with two commonly used bronchodilators, intended to 
provide a benchmark against which sibenadet activity could be judged. In all, 701 patients were randomized to one of three 
sibenadet dose groups (400, 600 or 1000 lig ex valve), salbutamol 200 ~g, ipratropium bromide (IB) 40 pg or placebo, all 
three times daily via pressurized metered dose inhaler (pMDI) for 4 weeks. Once the results of Study I had been evaluated, 
a dose-ranging, study (Study 2) involving 872 patients randomized to receive sibenadet (45, 270, or 495 I~g ex actuator), or 
placebo all three times daily via pMDI, for 6 weeks commenced. Both studies were preceded by a 2-week baseline phase 
and followed by a 2-week follow up period.The primary efficacy variable identified changes in key COPD symptoms over 
the treatment period (compared with baseline data) as determined by the novel Breathlessness, Cough and Sputum Scale 
(BCSS©). In addition, data on lung function, health-related quality of life and adverse events were collected. 
Patients receiving sibenadet therapy three times daily exhibited statistically significantly greater improvements in BCSS total 
score than those receiving placebo or bronchodilator therapy alone. A clear dose-response was evident in Study 2. 
Symptom improvement in this study was also accompanied by improved lung function and health-related quality of life. 
Sibenadet therapy was well tolerated with an adverse events profile comparable to current bronchodilator therapy, These 
data were viewed as extremely encouraging, warranting further, large-scale clinical investigation. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) refers 
to a disease spectrum with slowly progressive, poorly 
reversible airways obstruction due to chronic bronchitis, 
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emphysema, small airways disease or a combination of 
these conditions. The single greatest risk factor for the 
development of COPD is long-term tobacco smoking, 
which accounts for 80-90% of all cases (I). However, 
only around 15% of smokers go on to develop COPD. In 
non-smokers, COPD can be attributed to environmental 
pollution, occupational hazards and genetic abnormalities 
(2). Although many patients remain undiagnosed, the 
global prevalence is thought to be 4-6% in those over 
45 years of age (2). The impact of COPD continues to 
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intensify as the trend towards increased smoking in 
women continues (3). In addition, COPD is likely to 
become a particular problem in developing nations, 
where both life expectancy and cigarette smoking are 
increasing (4). Mortality projections reflect this situation, 
predicting that COPD will become the third leading 
cause of death worldwide by 2020 (5). The associated 
economic burden of COPD is considerable. In the 
U.S.A., the total healthcare expenditure for COPD is 
approximately twice that of asthma (6). 
In contrast to asthma, the airflow obstruction experi- 
enced by patients with COPD is largely irreversible.The 
Global Initiative on Obstructive Lung Disease (GOLD) 
guidelines have identified breathlessness, cough and 
sputum as the key symptoms associated with COPD (7), 
the chronic nature of which results in progressive 
impairment of health-related quality of life (HRQL), 
limiting individual activity and social functioning (8-10). 
The mechanisms underlying these key symptoms are 
poorly understood, but reflex activation of sensory 
afferent nerves by irritants is known to induce broncho- 
spasm, cough, and sputum production (10,1 I). This 
process normally acts as a protective mechanism to 
prevent contamination of the lung by irritant chemicals, 
dust or smoke, but in patients with COPD constant 
activation of sensory nerves in the airways may 
contribute to their symptoms. It has been shown that 
activation of D2-receptors in the periphery can modulate 
neuronal activity, generally in an inhibitory manner (12) 
and dopamine can inhibit the discharge of rapidly 
adapting receptors in the dog lung (13). In addition, 
D2-receptor mRNA has been demonstrated in the 
ganglia of sensory nerves associated with reflex 
pathways (14).The driving hypothesis for the develop- 
ment of new treatments was that stimulation of 
D2-receptors present on sensory nerves in the lung 
could suppress reflex-mediated COPD symptoms (15). 
Sibenadet HCI (ViozanTM,AR-C68397AA) is a dual D 2 
dopamine receptor, ~2-adrenoceptor agonist that com- 
bines the bronchodilator activity of a ~2-adrenoceptor 
agonist with the sensory afferent modulating effects 
associated with D2-receptor agonism. Preclinical 
evaluation has shown sibenadet to have prolonged 
~32-agonist duration of action, resulting in effective 
bronchodilator activity. The D2-receptor agonist 
property has been shown to inhibit the response of 
sensory receptors to irritant stimuli in relevant animal 
models (16). In dog models driven by stimulation of 
sensory nerve activity, sibenadet has been shown to 
inhibit capsaicin-induced cough, histamine-induced 
tachypnoea, and reflex-induced mucus secretion (16). 
Cooling or cutting the vagus inhibited both the 
tachypnoea and mucus production responses, indicating 
their reflex origin. These effects of sibenadet were 
obtained in the presence of ~-blockade and were 
reversed by pre-treatment with D2-selective antagonists 
including the peripherally active antagonist domperidone. 
This suggests that they were mediated via dopamine 
D 2 receptors outside the central nervous system. This 
comprehensive evaluation provided convincing evidence 
of the mechanism of action of sibenadet and suggested 
important clinical potential. 
The results of the early clinical evaluation of sibenadet 
are reported here. An initial 'proof of concept' study 
aimed to determine the clinical potential of this novel 
agent by comparing the effect on key COPD symptoms 
of a range of doses of sibenadet with that of placebo, and 
with common bronchodilator therapies (salbutamol or 
IB) included to provide a benchmark against which 
sibenadet activity could be judged. The results of this 
trial led to a second, dose-ranging, study to investigate 
the clinical efficacy and tolerability of sibenadet across a 
range of doses in comparison with placebo. These studies 
represent the first use of the novel Breathlessness, 
Cough and Sputum Scale (BCSS©), a unique patient- 
reported outcome tool designed to detect symptomatic 
changes in patients with COPD ( 17,18). 
METHODS 
Study design 
The clinical evaluation reported here comprised two 
multicentre, double-blind, placebo-controlled studies. 
Study I was a 4-week 'proof of concept' study designed 
to investigate the clinical efficacy of sibenadet in patients 
with COPD, using bronchodilator therapy as a 
benchmarlc This study was conducted in 69 centres in 
eight European countries and Canada. After clinic 
screening, patients entered a 2-week baseline period at 
the end of which eligible patients were randomized to 
one of three sibenadet dose groups (400, 600 or 1000 ~tg 
ex valve), salbutamol 200 ~tg, IB 40 I~g or placebo all by 
pMDI three times daily for a total of 4 weeks.A follow- 
up visit took place 2weeks after the end of the 
treatment period. As bronchodilators were included as 
controls rather than comparators, three times daily 
dosing of IB and salbutamol was considered sufficient to 
achieve the purpose of this study and a complex double 
dummy study design to enable a more conventional 
dosing frequency of four times daily was not adopted. 
Study 2 was a 6-week dose-ranging study, conducted in 
77 centres in Europe and 19 centres in the U.S.A. After 
completing a 2-week baseline period, eligible patients 
were randomized to receive sibenadet (45, 270, or 
495 ~g exactuator), or placebo via pMDI, three times 
daily, for 6 weeks followed by a 2-week follow-up period. 
The three sibenadet doses were selected on the basis of 
the findings from Study I. In both studies, patients were 
assessed at clinic visits on entry to the study, at the start 
of treatment, after 2 weeks' treatment, at the end of 
treatment and at the end of follow-up. 
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In both studies, patients were required to discontinue 
any routine inhaled long-acting bronchodilators during 
the baseline and treatment periods and short-acting 
bronchodilators during the treatment period. Other 
regular medications (corticosteroids, mucolytics and 
methylxanthines) could be continued providing a 
constant dose was maintained for the duration of the 
study. A short-acting inhaled 132-agonist (salbutamol 
[Ventolin TM, GlaxoSmithKline] pMDI, 1001~g per 
actuation, exvalve) was provided for use as rescue 
therapy.Throughout the study, patients were required to 
complete daily diary cards recording symptoms, morning 
and evening peak expiratory flow (PEF) measurements, 
rescue medication usage, changes in concomitant 
medication and any adverse events (AEs). 
The studies were performed in accordance with the 
Declaration of Helsinki and approved by Ethics 
Committees at each centre. All patients gave written 
informed consent. 
Patient population 
Male and female patients between 45 and 75 years of age 
with stable, smoking-related COPD (smoking history of 
> 15-pack-years) were eligible for inclusion in these 
studies if symptoms had persisted for >2years. At 
screening, they were required to have a forced 
expiratory flow in one second (FEVI) 20-70% of 
predicted normal and a FEVt/FVC (forced vital capacity) 
ratio of < 65%. In Study I, patients were additionally 
required to meet at least two of the following criteria: no 
atopy history; < 15% reversibility, or an increase in FEV t 
of < 200 ml, after inhaled salbutamol (400 ~g); prior 
evidence of diffusing capacity < 80% of predicted normal; 
previous evidence of emphysematous change on CT scan 
or X-ray, excluding over-inflation. In Study 2, an addi- 
tional criterion was included to ensure qualifying patients 
were symptomatic; at the end of the baseline period, 
patients were required to have a mean daily BCSS total 
score of _> 2 over any 7 consecutive days to qualify for 
randomization. 
Subjects were excluded if they had a history of a 
respiratory tract disorder other than COPD; onset of 
symptoms of chronic airways disease before the age of 
35 years; reversibility in FEV t greater than 200 ml or 15% 
increase from baseline after inhalation of 400 Ilg 
salbutamol; significant exacerbation of COPD in the 
previous 6 weeks (defined as requiring prescription of 
antibiotics or a change in oral/inhaled corticosteroid 
and/or methylxanthine therapy or requiring hospitali- 
zation); if they required domiciliary oxygen; exhibited 
laboratory abnormalities considered to be clinically 
significant or used any disallowed medications (inhaled 
long-acting bronchodilators, anticholinergics, oral 
13-agonists, leukotriene antagonists, dopamine agonists or 
antagonists, 13-adrenoceptor blockers, antibiotics for 
respiratory tract infections, or initiation of any anti- 
tussives, decongestants, mucolytics or proprietary 
medicines intended to reduce sputum production and/or 
cough). 
Outcome measures 
Primary efficacy variable 
The primary efficacy variable for both studies was the 
change in BCSS total score from the mean over the 
baseline period to the mean over the treatment period. 
Changes from baseline to each week and each 2-week 
period within the treatment period were also examined 
in Studies I and 2 respectively. In Study I the planned 
primary comparisons were between the 1000~g 
sibenadet dose and IB, salbutamol and placebo. 
In Study I, BCSS item scores (breathlessness, cough 
and sputum) were recorded in the daily diary card on a 
scale of I (no symptoms) to 5 (worst symptoms), with 
the BCSS total score being the sum of all three and 
ranging from 3 to 15. It was, however, noted that some 
patients recorded zero if they had no symptoms, rather 
than score I as defined in the original BCSS design. 
Therefore, in Study2 (and subsequent clinical evalua- 
tions), symptoms were rated on a scale of 0 to 4, the 
BCSS total score consequently ranging from 0 to 12. 
Assessment of lung function and rescue medication use 
In both studies, PEF was recorded at home morning and 
evening, prior to the administration of study or rescue 
therapy. The number of actuations of rescue medication 
used was recorded daily. 
Measurements of FEV i, FVC and slow vital capacity 
(SVC) were determined at every study visit except 
follow-up and patients were asked not to use any 
bronchodilator medication, including the study 
medication, for 4 hours prior to spirometric assess- 
ments. Measurements were made, where possible, at the 
same time of day, using the same spirometer and a 
standard technique at each centre. SVC was measured 
before forced expiratory manoeuvres, and the best of 
three separate measurements was used.Three separate 
manoeuvres were also used to measure FEV I and FVC 
with the best one recorded. 
In Study 2, a subset of patients with FEV I reversibility 
of 5 to 15% of baseline, were identified to determine the 
bronchodilator properties of sibenadet at the start and 
end of the treatment period. FEV I was recorded pre- 
dose and at 5, 15, 30, 45, 60, 90, 120 minutes and hourly 
thereafter until 8 hours after dosing. Using the 
trapezoidal rule, bronchodilation was summarized as the 
area under the FEV t time curve from 0 to 
8 hours (AUC0_sh FEVI), as litres per second over time. 
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Health-related quality of life (HRQL) 
HRQL was assessed at the beginning and end of the 
treatment periods using the patient-completed St 
George's Respiratory Questionnaire (SGRQ) (19) in all 
countries except the Czech Republic, Hungary, and 
Poland, where linguistic validation of the SGRQ 
questionnaire had not been performed. 
Safety measurements 
Incidence and severity of adverse events were recorded 
throughout he two studies. Heart rate, blood pressure, 
electrocardiogram, and blood and urine samples for 
routine haematology, clinical chemistry, and urinalysis, 
were evaluated at the beginning and end of the treatment 
period in all patients. 
Statistical analyses 
In both studies, all patients who were randomized and 
received at least one dose of study medication were 
included in the Intent to Treat (ITT) and safety 
populations upon which the efficacy and safety analyses 
were respectively based. Patients were analysed according 
to the treatment hey received. In both studies, the BCSS 
total scores for patients who discontinued prematurely 
from the study were imputed based on the mean of the 
BCSS total score on the last 3 days of treatment. Unless 
otherwise stated, all statistical testing was two-sided at 
the 5% significance level. 
In Study I, the changes in mean score from baseline in 
BCSS total and item scores were analysed for each of the 
weekly treatment periods and over the whole treatment 
period, using a non-parametric Mack-Skillings test (20). 
Pairwise median differences and adjusted 95% confidence 
intervals (CI) were calculated, based on the Wilcoxon 
Rank Sum test. This methodology was also used in the 
analysis of the SGRQ data. For lung function 
measurements (FEV I and FVC, measured in the clinic, and 
PEF assessments, recorded in the diary cards) an analysis 
of variance (ANOVA) model was used with treatment 
and country as fixed factors. The median number of 
actuations of rescue medication per day was analysed in 
the same way as BCSS total score. The primary 
comparisons (1000 ~g sibenadet vs. placebo, salbutamol 
and IB) were made at the 1.7% significance level. 
In Study2, the changes from baseline in mean BCSS 
total and item scores were analysed for each 2-weekly 
treatment period and over the whole treatment period 
using ANCOVA with treatment and centre as fixed 
factors and mean baseline score as a covariate. The 
least squares (LS) means, SEs and corresponding 95% CIs 
were derived. Spirometric, PEF, rescue medication and 
SGRQ data were analysed using the same methodology. 
It was planned to randomize 750 patients into 
Study I so that a minimum of 600 patients (100 per 
treatment group) would complete the study. This was 
based on results observed in the National Mucolytic 
survey (21) where a difference between treatments in 
global assessment of 0.92 with a SD of 2.968 was 
observed; 600 completed patients would allow a 
treatment difference of 1-37 in BCSS total score to be 
detected at the 1.7% level of significance with 80% 
power, using two-sided tests. Based on the results from 
Study I, it was planned to randomize 865 patients into 
Study 2 so that a minimum of 720 patients (180 per 
treatment group) would complete the study. Assuming 
a SD of 1-46 this would allow the detection of a 
difference of 0-5 in the BCSS total score between 
sibenadet and placebo, using two-sided testing at the 
5% significance level with 90% power. 
RESULTS 
Patient demographics 
Patient disposition for studies I and 2 is summarized in 
Figure I. In both studies, failure to complete was 
primarily due to adverse events, deterioration of patient 
condition, withdrawal of consent or a protocol deviation. 
Withdrawal rates were similar between the treatment 
groups and there were no obvious differences in the 
reasons for withdrawal. Patient demographics and 
baseline characteristics are outlined in Table I. Any 
differences noted between treatment groups at baseline 
were deemed random and not considered to influence 
the endpoints of this study. Compliance with study 
therapy assessed from daily diary entries was over 90% 
in all treatment groups. 
Efficacy of sibenadet in relieving key 
COPD symptoms 
Data from Studies I and 2 were derived using different 
analytical approaches and the results of these analyses 
are therefore discussed separately throughout. The 
results of the proof of concept study (Study I) 
demonstrated a reduction from baseline in mean daily 
BCSS total score over the 28-day treatment period in 
patients treated with sibenadet. When compared with 
placebo, this improvement was statistically significant 
with all doses of sibenadet, with the greatest reduction in 
total score seen with the 600 I~g dose (Figure 2a).There 
were small reductions from baseline in mean BCSS total 
score with salbutamol and IB.The change from baseline 
in mean BCSS total score in the sibenadet 600 Ilg dose 
group was also greater than that in the salbutamol and IB 
groups (Figure 2b). 
In study2, the change from baseline in mean BCSS 
total score over the course of the study (weeks I-2, 3-4 
and 5-6) was seen to be dose-related, with the smallest 
change in the 45-~tg roup and the largest change in the 
sibenadet 495-1~g group (Figure 3). The most marked 
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decreases were seen in the early weeks of the study.The 
LS mean changes from the baseline period to the full 
6-week treatment period in mean daily BCSS total score 
were -0.22, -0.44 and -0"55 for the sibenadet 45, 270 
and 495-~g groups respectively and -0.16 for the 
placebo group.The corresponding LS mean differences in 
these changes between placebo and each of the three 
sibenadet groups show that the two highest doses of 
sibenadet produced statistically significantly greater 
changes in mean daily BCSS than placebo (Figure 4). 
BCSS item scores 
In Study I, the reduction between mean breathlessness 
scores over the baseline period and the treatment 
period was greater in the sibenadet groups than in the 
placebo group.The median differences from placebo and 
95% CIs were 400/1g: -0-1 (-0"3, -0.1), 60011g: -0.3 
(-0.4, -0.2), 1000 I~g: -0"2 (-0"3, -0" I). However, neither 
cough nor sputum item scores differed between 
treatments.  
In Study 2, the dose response seen with the BCSS total 
scores was also reflected by the i tem scores.The mean 
daily Breathlessness cores decreased from baseline in all 
treatment groups, with the greatest effect seen in the 
first 2 weeks. Over the 6-week period, the LS mean 
differences (+ SE) between the sibenadet (45, 270 and 
495 I~g) groups vs. placebo were -0.04 ± 0"05 (95% CI 
-0.14 to 0.06),-0.13 ± 0.05 (95% C1-0.23 to -0"03) and 
-0.14 + 0.05 (95% CI -0-24 to -0.04) respectively. 
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FIGURE 2. Mean changes in BCSSTotal Score (days 4-28) from baserine: comparison of three sibenadet doses and placebo (sibenadet 
400 I~g vs. placebo P=O'O 15, sibenadet 600 t~g vs. placebo P < 0-001, sibenadet I000 Ilg vs. placebo P=0-O09); comparison of sibenadet 
vs. salbutamol and IB (sibenadet 600 Ilg vs. placebo P < 0"001, IB 40 Ilg vs. placebo P--0.505, salbutamol 200 I~g vs. placebo P--O. 149). 
Mean daily Cough scores decreased from baseline in 
all treatment groups. The LS mean difference (+ SE) 
between the sibenadet (45,270 and 495 ~tg) and placebo 
groups being-0"02 + 0.06 (95% CI -0.12 to 0.09), 
-0.08 + 0"05 (95% CI -0.19 to 0-03) and -0.13 + 0"05 
(95% CI -0.23, -0.02) respectively. 
Mean daily Sputum scores decreased from baseline in 
the two higher dose sibenadet groups only and the 
sibenadet 45-~tg group showed no differences from 
placebo. The LS mean difference (+ SE) between the 
sibenadet 270 and 495-1~g and placebo groups were, 
however, -0.06 + 0"05 (95% CI -0.16 to 0.04) and 
-0" 12 + 0-05 (95% CI -0.22 to -0.02). 
Assessment of lung function and rescue 
medication use 
In comparison with placebo, all sibenadet treatment 
groups (in both studies) demonstrated increased 
morning and evening PEF values over the entire study 
period, compared with baseline. In Study I, the increases 
in PEF values for all sibenadet groups were statistically 
significantly greater than increases seen in the placebo 
and IB groups, with a trend towards superiority for 
sibenadet when compared with salbutamol (data not 
shown). No statistically significant improvement in FEV e 
or FVC as measured at clinic visits were seen in any 
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FIGURE 4. Plot of LS mean BCSS total scores and corresponding 95% confidence intervals; data show the difference between each 
sibenadet group and placebo in absolute changes from baseline over the full 6-week treatment period (data from Study2). 
group. In Study 2, the increases in PEF over the 6-week 
treatment period were statistically significant (P < 0"001 ) 
compared with placebo for the 270 and 495 I~g doses 
(Table 2). In addition, small increases in FEV I, FVC and 
SVC were seen with all doses of sibenadet after 2 weeks' 
treatment and at the end of the treatment period 
(Table 2). 
In Study I, the use of rescue bronchodilator 
medication (measured as a mean value over the entire 
treatment period) was similar across the active 
treatment groups whilst more rescue medication was 
required in the placebo group. Mean (+ SD) use of rescue 
medication over the 4-week treatment period in patients 
on active medication ranged from a minimum of 
1.8 + 2-97 actuations per day in the salbutamol group to 
a maximum of 2.2 + 2.81 and 2.2 + 3-18 actuations per 
day in the IB and sibenadet 600 l~g groups, respectively. 
Rescue medication use in the placebo group was 
3. I + 3"92 actuations per day. 
In Study2, rescue bronchodilator medication usage 
(measured as change in mean values over the entire 
treatment period compared with baseline values) was 
reduced in the sibenadet 270 and 495-~g groups with LS 
mean (+ SE) reductions over placebo in both groups of 
1.2 + 0-27 puffs per day (95% CI - I .7  to -0.6 and - I .7  
to -0.7 respectively). 
Bronchodi lator assessment 
Serial FEV I measurements, performed in a subset of 
patients in Study 2, at the start and end of the 6-week 
treatment period, demonstrated bronchodilation in all 
sibenadet groups 5 minutes after dosing (the first 
measurement ime point) (Figure 5).At the start of the 
treatment period for the first assessment, 104 patients 
were included, of whom 85 completed the full 8-h 
assessment (drop-out rates were 10, 12.5, 16 and 29% 
for the 45, 270, 495-~g sibenadet doses and placebo 
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respectively). The mean (+ SD) maximum increases in 
FEV I for the 45, 270 and 495-11g sibenadet groups were 
0"26+0.18, 0.44+0"40, and 0-33+0.19 litres, 
respectively compared with 0.11+ 0.13 litres with 
placebo.The time to reach maximum FEV I was similar in 
all sibenadet groups at approximately 2 hours after 
treatment. 
At the end of the 6-week treatment period, 84 patients 
took part in the bronchodilator assessment, of whom 
67completed the full 8-h timecourse (drop-out rates 
were 15, 21, 23 and 14% for the 45, 270, 495-1ig 
sibenadet doses and placebo respectively).The pattern of 
changes was similar to that seen at the start of the study 
period, although the changes in FEV I were less marked. 
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Health-related quality of life 
In Study I, SGRQ data were available for approximately 
52% of patients due to the non-availability of linguistically 
validated questionnaires in some countries. For all the 
scores, the changes from baseline were generally small, 
with large standard deviations, reflecting variability in the 
data.There were median reductions of the overall score 
from baseline values in the groups receiving sibenadet 
4001~g, or 1000 ~g or salbutamol, no change in the 
sibenadet 600-1~g group and small increases in the 
placebo and IB groups. 
In Study 2, SGRQ data were available for 
approximately 85% of patients.At the end of the 6-week 
study period, the SGRQ overall score and each domain 
score had decreased for all three sibenadet dosage 
groups (Figure 6). For the 270 and 495-1~g doses, these 
changes were statistically significant when compared 
with placebo. 
Safety assessments 
In both studies, no clinically relevant changes in mean 
laboratory values, vital signs or ECG variables were seen. 
Treatment emergent adverse events reported in Study I 
by > 5% of patients in any group are summarized in 
Table 3. Treatment-emergent was defined as an event 
which was not present prior to administration of the 
first dose of study medication, but which became 
apparent after dosing, or a pre-existing event which 
worsened following dosing. There were no marked 
differences between the adverse event profiles of 
sibenadet, salbutamol or IB, except for the higher 
frequency of tremor in patients treated with sibenadet 
1000 I~g and taste of treatment at all doses of sibenadet. 
Eleven patients from the sibenadet 1000-1~g group 
discontinued treatment due to one or more adverse 
events compared with five patients from the sibenadet 
600-1~g roup. Of the I I patients on the 1000-t~g dose, 
seven discontinued treatment due to tachycardia and/or 
tremor. In the placebo group, ten patients discontinued 
treatment due to adverse events, nine of these 
withdrawals were due to worsening symptoms of 
COPD. There were three deaths during the study: one 
in the sibenadet 400-11g group following an exacerbation 
of COPD, one in the sibenadet 1000-1~g roup due to 
sepsis originating from pyelonephritis and one in the 
placebo group attributed to cardiac arrest. In total, 
12 patients experienced non-fatal serious adverse events 
during or following study treatment. These included 
three on placebo, one on salbutamol, one on IB and 
three, three and four on sibenadet 400-11g, 600-1~g and 
1000-1~g, respectively. 
Study2 also showed sibenadet to be generally well 
tolerated.The most commonly occurring adverse events 
that were reported more frequently at any sibenadet 
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dose than placebo were: back pain, tremor, nausea, 
bronchitis, dyspnoea and aggravated dyspnoea, 
respiratory infection and discernible taste of treatment. 
Respiratory system disorders were the most commonly 
reported category of adverse event, with the lowest 
frequency reported in the sibenadet 495-/~g roup (25%) 
and highest frequency in the 45-~g group (38%); 
reporting of respiratory events was 32% in the placebo 
group. Coughing, COPD and respiratory infection all 
occurred with lowest frequency on the sibenadet 495-1~g 
dose, and with a lower frequency than on placebo. 
Twenty-three patients suffered non-fatal serious adverse 
events during the treatment period, six in the 45-~g 
group, six in the 270-tlg group, seven in the 495-~tg roup, 
and four in the placebo group. The number of serious 
adverse events considered as possibly or probably 
related to study treatment was similar across the four 
treatment groups (sibenadet 45 ~tg and 270 t~g: three; 
sibenadet 495 tig: four; placebo: two). During the 
treatment period, one patient in the placebo group died 
because of respiratory insufficiency. Three deaths 
occurred during the follow-up period (two attributed to 
myocardial infarction, one in the sibenadet 45-~tg group 
and one in the 270-11g group; and one attributed to 
pneumonia in the 270-1~g roup). No deaths occurred in 
the highest dose sibenadet group. Ninety-one patients 
discontinued treatment either permanently or 
temporarily as a result of an adverse event during the 
treatment period, with a similar number in each group. 
DISCUSSION 
The hypothesis underlying the development of the novel 
D2-receptor agonist effect of sibenadet is based on the 
knowledge that, breathlessness, cough and excessive 
mucus production, can all be mediated through 
stimulation of pulmonary sensory afferent nerves (11). 
Studies of animal models of COPD symptoms have 
demonstrated the efficacy of sibenadet in controlling 
such symptoms via its D 2dopamine receptor agonist 
effect (I 6). The data from these in vivo studies indicate 
that dopaminergic agonists provide potentially 
therapeutic benefits, probably by acting on sensory 
nerves. In support of these findings, expression of 
D2dopamine receptors on the sensory neurones of 
thoracic dorsal root ganglia has recently been 
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demonstrated at the level of both mRNA and protein 
(22). 
The results of the studies reported here provided 
clinical corroboration of the sibenadet hypothesis and 
preclinical findings.The initial proof of concept study was 
designed to determine the clinical potential of sibenadet 
therapy and indeed the dual D 2dopamine, ~2-adreno- 
ceptor agonist effect of sibenadet was seen to improve 
the key COPD symptoms of breathlessness, cough and 
sputum in this 28-day study.This study also piloted the 
BCSS and highlighted its potential for use in future 
studies. This novel instrument has subsequently under- 
gone a rigorous evaluation process to demonstrate its 
reproducibility, reliability and validity, thereby confirming 
its value in symptom assessment (17,18). As a proof of 
concept trial, Study I was not intended to demonstrate 
dose-response and indeed, greatest efficacy was 
observed in the sibenadet 600-~g dose group, with 
statistically significant reduction in BCSS total and item 
scores. It is possible that the 1000-1~g sibenadet dose 
was less well tolerated than the lower dose,with adverse 
effects resulting in the patient feeling generally less well, 
thereby masking any additional efficacy afforded by the 
higher dose. This dose was not used in further studies. 
In contrast to the observed efficacy of sibenadet, 
salbutamol and IB produced only limited symptomatic 
improvements. These findings were, however, viewed 
with caution as a potentially sub-optimal therapeutic 
regimen was adopted for both comparators (i.e. three 
times daily rather than four times daily), in order to 
simplify the study design.This was considered warranted 
as the primary objective of the study was not 
comparative. Currently available therapy does little to 
improve the characteristic symptoms of breathlessness, 
cough, and sputum associated with COPD. Comparison 
with these bronchodilators offered validation of D 2 
effects of sibenadet and therefore proof of concept for 
future development of this potentially useful novel 
therapy. 
The symptomatic improvement observed in Study I 
provided the impetus for undertaking a second study 
designed to determine the therapeutic dose for 
sibenadet. This objective was clearly achieved, as dose- 
related improvements in BCSS total and item scores 
with sibenadet therapy were observed. The highest dose 
(495 l~g) achieved greatest efficacy without compro- 
mising safety and therefore a 500-1~g dose, delivered in 
two equal fractions, was used in subsequent large-scale 
studies (23). 
COPD is typically associated with significant 
impairment of HRQL. Patients will generally tolerate 
disease symptoms, tending to present to healthcare 
professionals only when they recognize a decline in their 
ability to perform everyday activities (8,23). Assessment 
of HRQL is therefore an important, clinically meaningful 
therapeutic outcome measure in COPD (25,26). It is 
important to note that, in Study 2, the symptomatic 
benefits of sibenadet therapy were accompanied by 
statistically significant improvements in SGRQ overall 
and all domain scores at the two higher doses. These 
results also indicate a clinically meaningful improvement 
over placebo (as defined by a change in total score of 
>4.0) (19). While the SGRQ was not specifically 
designed to detect short-term changes in HRQL there 
was cause for optimism as sibenadet herapy appeared to 
demonstrate a rapid, positive effect on HRQL. However, 
as the SGRQ was originally developed to detect 
differences in HRQL in patients with asthma over the 
course of a year, it is possible that the short-term 
improvements observed could be artefactuaI.Treatment- 
related improvements in HRQL seen in Study I were less 
clear than those obtained in Study 2, possibly due to the 
small number of patients from which SGRQ data were 
obtained and the shorter study period. 
Although predictable effects mediated by ~2-adreno- 
ceptor stimulation occurred more often with sibenadet, 
particularly at the highest dose in both studies, the 
overall frequency for reporting adverse events was low. 
The incidence of adverse events associated with D 2 
agonists (such as nausea and vomiting) was low and 
similar to that reported in the bronchodilator groups, 
supporting the lack of centrally mediated D 2 effects with 
sibenadet use.While there was a relatively high incidence 
of discernible taste of treatment with sibenadet, no 
patient withdrew from the study because of this effect 
alone.The overall safety profile of sibenadet appeared to 
be acceptable and subsequent large-scale evaluation has 
demonstrated a similar safety profile with no additional 
safety concerns (23). 
While these early clinical studies were extremely 
encouraging, it is possible, especially with the benefit of 
hindsight, to detect some early evidence of reduced 
sibenadet effect over time. In Study 2, the change from 
baseline in BCSS total score was seen to decrease in the 
first 2 weeks of the study, whereas by weeks 5-6 a return 
towards baseline values was seen. In the light of the 
results of the longer-term studies (23)these results 
could be interpreted as early indicators of the 
tachyphylaxis een with increased treatment duration. 
These longer-term observations, however, were 
obviously not known at the time and the decision to 
progress to Phase III development was justifiable. 
In conclusion, the results of the early sibenadet clinical 
evaluation reported here indicated that this novel 
combination of a D 2 dopamine receptor and ~2-adreno- 
ceptor agonist had important clinical potential for the 
treatment of COPD.The positive effects of sibenadet on 
COPD symptoms, HRQL and lung function appeared to 
be dose-related. Although these data appeared 
encouraging, it was acknowledged that the true potential 
of sibenadet for the symptomatic relief of COPD could 
only be determined from large-scale, long-term clinical 
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investigation. These studies have now been completed 
and have shown that the early clinical benefit observed in 
the studies reported here was not sustained in studies of 
longer duration (23). 
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